https://mindmedicinelaw.com/briefing/dea-schedules-mdmb-4en-pinaca-as-schedule-i-substance-20260424-170Psychedelic Research Journalen2026-04-24T15:06:19.469792+00:00DEA Schedules MDMB-4en-PINACA as Schedule I SubstanceMDMB-4en-PINACA, DEA, Schedule I, synthetic cannabinoids, Controlled Substances Act, drug policy, research restrictions, regulatory controls, international treaties, public health riskshttps://mindmedicinelaw.com/briefing/psilocybin-and-alternatives-for-treatment-resistant-depression-20260422-44Psychedelic Research Journalen2026-04-24T15:06:52.426178+00:00Psilocybin and Alternatives for Treatment-Resistant Depressiontreatment-resistant depression, psilocybin, ketamine, esketamine, vagus nerve stimulation, alternative treatments, clinical trials, mental health, psychedelic therapy, depression treatmenthttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-treating-depression-and-anxiety-a-review-20260422-207Psychedelic Research Journalen2026-04-24T15:06:37.610098+00:00Psilocybin's Role in Treating Depression and Anxiety: A Reviewpsilocybin, depression treatment, anxiety therapy, neuroplasticity, clinical trials, mental health, serotonergic agonist, treatment-resistant, PRISMA guidelines, brain networkshttps://mindmedicinelaw.com/briefing/synaptic-density-and-depression-in-parkinson-s-new-insights-20260421-254Psychedelic Research Journalen2026-04-24T15:07:31.092220+00:00Synaptic Density and Depression in Parkinson's: New Insightssynaptic density, Parkinson's disease, depression, neurobiology, PET imaging, synaptic plasticity, mood circuitry, clinical trials, mental health, radiotracerhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-depression-meta-analysis-insights-20260421-80Psychedelic Research Journalen2026-04-24T15:07:17.557871+00:00Psilocybin Therapy for Depression: Meta-Analysis Insightspsilocybin therapy, depression treatment, meta-analysis, randomized controlled trials, psychedelic research, clinical trials, methodological limitations, phase 3 trials, mental health, evidence-based medicinehttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-postoperative-care-for-elderly-crc-patients-20260421-93Psychedelic Research Journalen2026-04-24T15:07:04.486076+00:00Esketamine's Role in Postoperative Care for Elderly CRC Patientsesketamine, postoperative depression, elderly patients, colorectal cancer, sufentanil, randomized controlled trial, psychological benefits, enhanced recovery protocols, NMDA receptor antagonist, patient satisfaction